369 related articles for article (PubMed ID: 32096671)
21. Excellent Repigmentation of Generalized Vitiligo with Oral Baricitinib Combined with NB-UVB Phototherapy.
Li X; Sun Y; Du J; Wang F; Ding X
Clin Cosmet Investig Dermatol; 2023; 16():635-638. PubMed ID: 36936753
[TBL] [Abstract][Full Text] [Related]
22. Phototherapy for Vitiligo: A Systematic Review and Meta-analysis.
Bae JM; Jung HM; Hong BY; Lee JH; Choi WJ; Lee JH; Kim GM
JAMA Dermatol; 2017 Jul; 153(7):666-674. PubMed ID: 28355423
[TBL] [Abstract][Full Text] [Related]
23. The early repigmentation pattern of vitiligo is related to the source of melanocytes and by the choice of therapy: a retrospective cohort study.
Yang K; Xiong X; Pallavi G; Ling Y; Ding F; Duan W; Sun W; Ding G; Gong Q; Zhu W; Lu Y
Int J Dermatol; 2018 Mar; 57(3):324-331. PubMed ID: 29318595
[TBL] [Abstract][Full Text] [Related]
24. Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation.
Komnitski M; Komnitski A; Komnitski Junior A; Silva de Castro CC
An Bras Dermatol; 2020; 95(4):473-476. PubMed ID: 32418716
[TBL] [Abstract][Full Text] [Related]
25. Tetrahydrocurcuminoid cream plus targeted narrowband UVB phototherapy for vitiligo: a preliminary randomized controlled study.
Asawanonda P; Klahan SO
Photomed Laser Surg; 2010 Oct; 28(5):679-84. PubMed ID: 20961233
[TBL] [Abstract][Full Text] [Related]
26. Targeted ultraviolet B phototherapy in vitiligo: A comparison between once-weekly and twice-weekly treatment regimens.
Majid I; Imran S
Indian J Dermatol Venereol Leprol; 2015; 81(6):600-5. PubMed ID: 26515839
[TBL] [Abstract][Full Text] [Related]
27. Narrowband UVB phototherapy in vitiligo: evaluation of results in 53 patients.
Percivalle S; Piccino R; Caccialanza M; Forti S
G Ital Dermatol Venereol; 2008 Feb; 143(1):9-14. PubMed ID: 18833047
[TBL] [Abstract][Full Text] [Related]
28. Vitiligo: Pathogenesis and New and Emerging Treatments.
Perez-Bootello J; Cova-Martin R; Naharro-Rodriguez J; Segurado-Miravalles G
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139134
[TBL] [Abstract][Full Text] [Related]
29. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.
Rosmarin D; Pandya AG; Lebwohl M; Grimes P; Hamzavi I; Gottlieb AB; Butler K; Kuo F; Sun K; Ji T; Howell MD; Harris JE
Lancet; 2020 Jul; 396(10244):110-120. PubMed ID: 32653055
[TBL] [Abstract][Full Text] [Related]
30. This Month in JAAD International: December 2022: Topical management of vitiligo with Janus kinase inhibitors.
Kantor J
J Am Acad Dermatol; 2022 Dec; 87(6):1284. PubMed ID: 36228949
[No Abstract] [Full Text] [Related]
31. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
[TBL] [Abstract][Full Text] [Related]
32. Combined treatment with fractional carbon dioxide laser, autologous platelet-rich plasma, and narrow band ultraviolet B for vitiligo in different body sites: A prospective, randomized comparative trial.
Abdelghani R; Ahmed NA; Darwish HM
J Cosmet Dermatol; 2018 Jun; 17(3):365-372. PubMed ID: 28834191
[TBL] [Abstract][Full Text] [Related]
33. Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo.
Niu C; Xie H; Aisa HA
Mini Rev Med Chem; 2021; 21(20):3203-3218. PubMed ID: 33823765
[TBL] [Abstract][Full Text] [Related]
34. Successful Treatment of Vitiligo Vietnamese Patients with Vitilinex® Herbal Bio-Actives in Combination with Phototherapy.
Van TN; Minh TT; Huu DL; Huu SN; Thanh TV; Huu ND; Cam VT; Huyen ML; Hau KT; Trong HN; Gandolfi M; Satolli F; Feliciani C; Tirant M; Vojvodic A; Lotti T
Open Access Maced J Med Sci; 2019 Jan; 7(2):283-286. PubMed ID: 30745981
[TBL] [Abstract][Full Text] [Related]
35. A Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo.
Grossmann MC; Haidari W; Feldman SR
J Drugs Dermatol; 2023 Jul; 22(7):664-667. PubMed ID: 37410047
[TBL] [Abstract][Full Text] [Related]
36. Targeted broadband ultraviolet b phototherapy produces similar responses to targeted narrowband ultraviolet B phototherapy for vitiligo: a randomized, double-blind study.
Asawanonda P; Kijluakiat J; Korkij W; Sindhupak W
Acta Derm Venereol; 2008; 88(4):376-81. PubMed ID: 18709309
[TBL] [Abstract][Full Text] [Related]
37. Repigmentation patterns induced by NB-UVB and their relationship with melanocytic migration and proliferation in vitiligo.
Castanedo-Cázares JP; Cortés-García JD; Fuentes-Ahumada C; Martinez-Rosales K; Torres-Álvarez B
Photodermatol Photoimmunol Photomed; 2016 Sep; 32(5-6):269-275. PubMed ID: 27627998
[TBL] [Abstract][Full Text] [Related]
38. Vitiligo treatment in childhood: a state of the art review.
Tamesis ME; Morelli JG
Pediatr Dermatol; 2010; 27(5):437-45. PubMed ID: 20553403
[TBL] [Abstract][Full Text] [Related]
39. Treatment of vitiligo using targeted UVB-Intense Pulsed Light (IPL)- phototherapy: evaluation of variables affecting therapeutic success.
Hartmann A; Schmidt-Habel A; Löhberg L; Zajitschek J; Englbrecht M; Eichner S; Schuler G
Eur J Dermatol; 2014; 24(5):551-9. PubMed ID: 25445089
[TBL] [Abstract][Full Text] [Related]
40. Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review.
Utama A; Wijesinghe R; Thng S
Int J Dermatol; 2024 Apr; ():. PubMed ID: 38610078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
